share_log

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $21

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $21

BTIG 維持對健康催化劑的買入,將目標價下調至21美元
Benzinga Real-time News ·  2022/09/26 08:13

BTIG analyst David Larsen maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $25 to $21.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論